Table 5.
Overall survival according to stage and treatment modalities
| N | Median | 1-year | 2-year | 3-year | |
|---|---|---|---|---|---|
| Characteristic | |||||
| Months (95% CI) | % (95% CI) | ||||
| IIIA | |||||
| Total* | 321 | 20.0 (17.1; 21.4) | 70.7 (65.9; 75.9) | 39.4 (34.3; 45.2) | 27.0 (21.8; 33.3) |
| Good | 223 | 21.4 (20.1; 25.8) | 76.3 (70.9; 82.1) | 45.6 (39.4; 52.8) | 33.8 (27.7; 41.3) |
| Poor | 75 | 13.3 (11.4; 17.7) | 57.3 (47.2; 69.7 | 23.2 (15.2; 35.2) | 9.1 (3.2; 26.0) |
| IIIB | |||||
| Total* | 262 | 14.4 (13.0; 15.9) | 58.2 (52.3; 64.5) | 27.5 (22.5; 33.7) | 13.5 (9.0; 20.2) |
| Good | 146 | 17.8 (14.8; 19.6) | 67.0 (59.8; 75.1) | 33.1 (26.1; 42.0) | 19.6 (13.2; 29.1) |
| Poor | 97 | 10.4 (8.8; 19.6) | 44.1 (35.2; 55.2) | 17.3 (11.1; 27.0) | 8.1 (3.0; 21.6) |
| T3N3 and T4N3** | 84 | 11.6 (9.8; 15.9) | 48.5 (38.8; 60.5) | 22.6 (15.2; 33.8) | 9.4 (3.9; 22.7) |
| IIIA+IIIB | |||||
| Total* | 583 | 16.8 (15.3; 18.5) | 65.1 (61.3; 69.1) | 34.1 (30.4; 38.2) | 21.0 (17.3; 25.4) |
| Good | 369 | 20.1 (18.0; 21.5) | 72.6 (68.2; 77.3) | 40.7 (35.9; 46.2) | 28.3 (23.6; 34.0) |
| Poor | 172 | 11.8 (10.2; 14.2) | 50.0 (42.9; 57.9) | 19.9 (14.6; 27.0) | 8.0 (3.6; 17.8) |
| Surgery | |||||
| All surgeries | 135 | 29.0 (27.1; NA) | 82.2 (76.0; 88.9) | 60.6 (52.8; 69.6) | 43.9 (35.2; 54.8) |
| Alone | 9 | 13.9 (3.2; NA) | 55.6 (31.0; 99.7) | 22.2 (6.6; 75.4) | 22.2 (6.6; 75.4) |
| Surgery plus CT or RT | 85 | 27.8 (23.6; NA) | 80.0 (71.9; 89.0) | 57.2 (47.5; 68.9) | 37.0 (26.7; 51.3) |
| Surgery plus adjuvant CT | 77 | 28.3 (24.7; NA) | 81.8 (73.6; 90.9) | 60.6 (50.6; 72.7) | 38.9 (28.0; 54.0) |
| Trimodality therapy | 41 | Not reached | 92.7 (85.0; 100) | 76.9 (64.7; 91.5) | 64.8 (49.9; 84.2) |
| Non-surgical therapy | |||||
| All non-surgical | 448 | 14.6 (13.7; 15.9) | 59.9 (55.5; 64.7) | 26.0 (22.1; 30.5) | 13.8 (10.2; 18.8) |
| CT alone | 150 | 12.7 (11.3; 13.9) | 56.5 (49.1; 65.0) | 19.1 (13.7; 26.8) | 6.2 (2.7; 14.4) |
| RT alone | 69 | 12.7 (9.6; 18.4) | 52.2 (41.6; 65.4) | 18.8 (11.6; 30.7) | 11.8 (5.9; 23.5) |
| CRT all | 200 | 19.6 (17.5; 21.6) | 72.9 (67.0; 79.3) | 36.9 (30.7; 44.5) | 22.6 (16.1; 31.6) |
| CRT sequential | 146 | 20.5 (17.2; 22.8) | 75.2 (68.5; 82.5) | 38.8 (31.5; 47.9) | 23.5 (16.2; 34.0) |
| CRT concurrent | 54 | 17.9 (14.6; 22.2) | 66.7 (55.2; 80.5) | 32.0 (21.6; 47.6) | 22.5 (12.7; 39.9) |
| HR (95% CI) | p-value | ||||
| IIIA vs. IIIB | 0.70 (0.58; 0.85) | < 0.001 | |||
| IIIA Good vs. IIIA Poor | 0.54 (0.40; 0.73) | < 0.001 | |||
| IIIB Good vs. IIIB Poor | 0.57 (0.43; 0.76) | < 0.001 | |||
| IIIA vs. IIIB Good | 0.86 (0.68; 1.09) | 0.212 | |||
| Tri-modality vs. Surgery plus adjuvant CT | 0.47 (0.25; 0.89) | 0.021 | |||
| CRT sequential vs. concurrent | 0.83 (0.57; 1.20) | 0.326 | |||
Good = performance status 0–1 and no weight loss; Poor = performance status 2–3 and/or weight loss ≥ 10%; CRT = chemoradiotherapy; CT = chemotherapy; RT = radiotherapy
* = Total is not sum of Good and Poor, as some patients had no data about weight loss;
** = Stage IIIC in Union for International Cancer Control [UICC] 8